Abstract 273P
Background
We compared the diagnostic performance of cognitive transrectal MRI-targeted biopsy (MRITB) between three anatomical zones of the prostate.
Methods
Of the 569 initial cases with suspected prostate cancer, those who received standard biopsy (14-region, 18-core biopsy: SB) between June 2019 and March 2023 were selected (SB 57 cases, SB+MRITB 509 cases). SB alone was performed in PI-RADS v2.1 ≦2, and MRITB was added in ≧3. In this study, we investigated whether zonal anatomy affects the diagnostic performance of MRITB retrospectively.
Results
In 569 cases, 394 cases (69.2%) were positive for cancer. Of 394 cancer cases, 25 (6.3%) were from SB alone and 369 (93.7%) from SB+MRITB. According to the Epstein criteria, 359 cases (91.1%) were clinically significant. In all cases, the diagnostic performance of MRITB was 80.1% for sensitivity, 20.5% for specificity, 71.4% for positive predictive value, 29.4% for negative predictive value, and 63.0% for accuracy. The true positive rates of cancer detection by MRITB in each zone were 22 cores (43.1%) in CZ, 125 cores (41.9%) in TZ, and 283 cores (64.6%) in PZ. CZ and TZ groups were significantly lower than the PZ group, respectively, and especially, midgland TZ was the highest false-positive rates compared to midgland-apex TZ (87.3% v.s.33.3%).
Conclusions
In the case of SB including apex anterior biopsy, MRITB alone missed clinically significant cancers in 65 cases (18.1%) in PI-RADS v2.1 ≥3, which was a higher rate than those reported by many previous reports. In contrast, MRITB showed a high false-positive rate especially in TZ, suggesting that the positive criteria and approach model for these lesions need to be discussed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Toyama.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract